Metabolic syndrome
Conditions
Interventions
Looking forward to the Western Medicine Group:None
Prospective Integrated Traditional Chinese and Western Medicine Group:None
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Retrospective Cohort Study Inclusion Criteria: Patients with a diagnosis of metabolic syndrome. Prospective Cohort Study: 1. Meet the diagnostic criteria for metabolic syndrome in international standards (such as NCEP-ATP III, IDF or Chinese criteria for metabolic syndrome), that is, meet at least three or more of the following: excessive waist circumference (>=90 cm for males and >=80 cm for females); elevated blood pressure (>=130/85 mmHg or using antihypertensive medications); elevated fasting blood glucose (>=5.6 mmol/L or diagnosed diabetes mellitus); dyslipidemia (triglycerides >=1.7 mmol/L or using lipid-lowering drugs); Decreased levels of high-density lipoprotein cholesterol (HDL-C) (1.0 mmol/L < men and 1.3 mmol/L < women). 2. Adults between the ages of 18 and 80 (both males and females can be included); 3. Belong to the high-risk group of coronary heart disease; 4. Willing to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Retrospective Cohort Study Exclusion Criteria: Those who are considered unsuitable by the investigator to participate in this study. Prospective Cohort Study: 1. Serious heart, lung, brain, and hematologic diseases, including but not limited to heart failure, within 2 weeks after acute myocardial infarction, unstable angina, ventricular tachycardia, ventricular fibrillation, etc.; 2. Patients with poor drug control with hypertension (>180/120mmHg) or patients with confirmed secondary hypertension; 3.Type 1 diabetes mellitus or other conditions in which blood sugar levels are extremely unstable; 4. Patients with severe hepatic and renal insufficiency; 5. Severe gastrointestinal diseases or digestive and absorption disorders (such as Crohn's disease, ulcerative colitis); 6. Have a definite infectious disease (such as active tuberculosis or HIV infection) or immunodeficiency state; 7. Individuals with a recent (past 6 months) history of cancer or who are undergoing cancer treatment; 8. Individuals who have participated in other clinical trials in the past 1 month and have used trial drugs; 9. Pregnant or lactating women; 10. Those with cognitive impairment, drug addiction, and severe alcoholism; 11. Coagulation dysfunction; 12. Allergy to traditional Chinese medicine decoction and its ingredients; 13. Individuals with a history of major surgery within the past 6 months or individuals who plan to undergo major surgery during the trial; 14. Other states that cannot meet the requirements of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coronary heart disease risk markers; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;Blood glucose;Blood pressure;Blood lipids; | — |
Countries
China
Contacts
Public ContactShi Shuai
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed